Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Caladrius Bio (CLBS)

Caladrius Bio (CLBS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,897
  • Shares Outstanding, K 60,583
  • Annual Sales, $ 0 K
  • Annual Income, $ -27,470 K
  • 60-Month Beta 0.93
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.38
Trade CLBS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.41
  • Most Recent Earnings -0.11 on 08/04/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 459.76% ( +326.81%)
  • Historical Volatility 42.52%
  • IV Percentile 88%
  • IV Rank 52.04%
  • IV High 858.53% on 06/14/22
  • IV Low 27.15% on 04/21/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 44
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 4,341
  • Open Int (30-Day) 5,147

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.10
  • Number of Estimates 3
  • High Estimate -0.07
  • Low Estimate -0.13
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4642 +9.16%
on 08/01/22
0.5939 -14.68%
on 07/12/22
-0.0642 (-11.25%)
since 07/08/22
3-Month
0.4019 +26.08%
on 05/12/22
0.5939 -14.68%
on 07/12/22
+0.0996 (+24.47%)
since 05/09/22
52-Week
0.4019 +26.08%
on 05/12/22
1.3400 -62.19%
on 09/01/21
-0.8133 (-61.61%)
since 08/09/21

Most Recent Stories

More News
Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata...

CLBS : 0.5067 (-0.65%)
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates PING, CLBS, MANT

/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

PING : 27.97 (-0.11%)
CLBS : 0.5067 (-0.65%)
MANT : 95.68 (-0.03%)
CALADRIUS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Caladrius Biosciences, Inc. - CLBS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Caladrius Biosciences, Inc. (NasdaqCM: CLBS)...

CLBS : 0.5067 (-0.65%)
Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease

Top-line data from all subjects expected by the first quarter of 2023...

CLBS : 0.5067 (-0.65%)
Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group

BASKING RIDGE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage...

CLBS : 0.5067 (-0.65%)
Caladrius Biosciences to Present at the BIO International Convention 2022

BASKING RIDGE, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage...

CLBS : 0.5067 (-0.65%)
Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction

Interim analysis to be conducted following enrollment suspension in the double-blind, randomized, placebo-controlled clinical trial Next development steps...

CLBS : 0.5067 (-0.65%)
Caladrius Biosciences to Present at the H.C. Wainwright Global Investment Conference

BASKING RIDGE, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage...

CLBS : 0.5067 (-0.65%)
CALADRIUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Caladrius Biosciences, Inc. - CLBS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Caladrius Biosciences, Inc. (NasdaqCM: CLBS)...

CLBS : 0.5067 (-0.65%)
Caladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update

Signs definitive merger agreement with Cend Therapeutics along with immediate investment and collaboration agreements Maintains strong financial...

CLBS : 0.5067 (-0.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve...

See More

Key Turning Points

3rd Resistance Point 0.5655
2nd Resistance Point 0.5470
1st Resistance Point 0.5269
Last Price 0.5067
1st Support Level 0.4883
2nd Support Level 0.4698
3rd Support Level 0.4497

See More

52-Week High 1.3400
Fibonacci 61.8% 0.9816
Fibonacci 50% 0.8709
Fibonacci 38.2% 0.7603
Last Price 0.5067
52-Week Low 0.4019

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar